BG64292B1 - К"Л'ИВИРАН... НА LAWSONIA INTRACELLULARIS, ВАК'ИНИ 'Р...(tm)" LAWSONIA INTRACELLULARIS И ДИАГНО''И-НИ 'Р...Д''ВА - Google Patents
К"Л'ИВИРАН... НА LAWSONIA INTRACELLULARIS, ВАК'ИНИ 'Р...(tm)" LAWSONIA INTRACELLULARIS И ДИАГНО''И-НИ 'Р...Д''ВА Download PDFInfo
- Publication number
- BG64292B1 BG64292B1 BG102130A BG10213097A BG64292B1 BG 64292 B1 BG64292 B1 BG 64292B1 BG 102130 A BG102130 A BG 102130A BG 10213097 A BG10213097 A BG 10213097A BG 64292 B1 BG64292 B1 BG 64292B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- intracellularis
- bacteria
- cells
- culture
- infected
- Prior art date
Links
- 241001148567 Lawsonia intracellularis Species 0.000 title claims abstract description 143
- 229960005486 vaccine Drugs 0.000 title claims abstract description 59
- 241000894006 Bacteria Species 0.000 claims abstract description 92
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000001301 oxygen Substances 0.000 claims abstract description 36
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 36
- 239000000725 suspension Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims description 64
- 241001465754 Metazoa Species 0.000 claims description 55
- 239000002054 inoculum Substances 0.000 claims description 31
- 230000002238 attenuated effect Effects 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000011081 inoculation Methods 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 145
- 241000282887 Suidae Species 0.000 description 59
- 208000015181 infectious disease Diseases 0.000 description 55
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 54
- 241000699800 Cricetinae Species 0.000 description 35
- 239000012091 fetal bovine serum Substances 0.000 description 32
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 30
- 239000002609 medium Substances 0.000 description 28
- 238000002255 vaccination Methods 0.000 description 28
- 239000001569 carbon dioxide Substances 0.000 description 27
- 229910002092 carbon dioxide Inorganic materials 0.000 description 27
- 230000012010 growth Effects 0.000 description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 21
- 239000001257 hydrogen Substances 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 210000003405 ileum Anatomy 0.000 description 18
- 210000003608 fece Anatomy 0.000 description 17
- 210000004877 mucosa Anatomy 0.000 description 17
- 239000007789 gas Substances 0.000 description 15
- 230000003902 lesion Effects 0.000 description 15
- 108010059993 Vancomycin Proteins 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 229960003165 vancomycin Drugs 0.000 description 14
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 14
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 12
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 12
- 229960003942 amphotericin b Drugs 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 208000004232 Enteritis Diseases 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 229910052709 silver Inorganic materials 0.000 description 9
- 239000004332 silver Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 229930193140 Neomycin Natural products 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 229960004927 neomycin Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229930182566 Gentamicin Natural products 0.000 description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 229960002518 gentamicin Drugs 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000011049 pearl Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 238000004114 suspension culture Methods 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 241000272517 Anseriformes Species 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 241000120551 Heliconiinae Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 238000012364 cultivation method Methods 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- YUKYSOJQDJMANI-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)[C@@H](N)CCC(O)=O YUKYSOJQDJMANI-DFWYDOINSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000037902 enteropathy Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- APKFDSVGJQXUKY-UPWJBAEMSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaen Chemical compound OC1C(N)C(O)C(C)OC1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-UPWJBAEMSA-N 0.000 description 1
- NUKQEEMKQGMUQH-UHFFFAOYSA-N 1-methyl-1-nitrosoguanidine Chemical compound O=NN(C)C(N)=N NUKQEEMKQGMUQH-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000666657 Homo sapiens Rho-related GTP-binding protein RhoQ Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038339 Rho-related GTP-binding protein RhoQ Human genes 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012733 comparative method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- CEAVGODCDNSBKB-QTNFYWBSSA-L potassium;sodium;(2s)-2-aminopentanedioate Chemical compound [Na+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O CEAVGODCDNSBKB-QTNFYWBSSA-L 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940007392 tylan Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
- C12N9/92—Glucose isomerase (5.3.1.5; 5.3.1.9; 5.3.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/465,337 US5714375A (en) | 1995-06-05 | 1995-06-05 | Ileal symbiont intracellularis propagation in suspended host cells |
| US08/658,194 US5885823A (en) | 1995-06-05 | 1996-06-04 | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
| PCT/US1996/009576 WO1996039629A1 (en) | 1995-06-05 | 1996-06-05 | Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG102130A BG102130A (bg) | 1998-09-30 |
| BG64292B1 true BG64292B1 (bg) | 2004-08-31 |
Family
ID=27041284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102130A BG64292B1 (bg) | 1995-06-05 | 1997-12-18 | К"Л'ИВИРАН... НА LAWSONIA INTRACELLULARIS, ВАК'ИНИ 'Р...(tm)" LAWSONIA INTRACELLULARIS И ДИАГНО''И-НИ 'Р...Д''ВА |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5885823A (cg-RX-API-DMAC7.html) |
| EP (5) | EP1655607B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP3765834B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR100758614B1 (cg-RX-API-DMAC7.html) |
| AT (3) | ATE289069T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU717045B2 (cg-RX-API-DMAC7.html) |
| BG (1) | BG64292B1 (cg-RX-API-DMAC7.html) |
| BR (2) | BRPI9612938B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2222643C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ295933B6 (cg-RX-API-DMAC7.html) |
| DE (5) | DE69634334T2 (cg-RX-API-DMAC7.html) |
| DK (3) | DK1403643T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2173055T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR07C0071I2 (cg-RX-API-DMAC7.html) |
| HU (1) | HU230199B1 (cg-RX-API-DMAC7.html) |
| LU (1) | LU91405I2 (cg-RX-API-DMAC7.html) |
| NL (1) | NL300331I2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ319994A (cg-RX-API-DMAC7.html) |
| PL (6) | PL187850B1 (cg-RX-API-DMAC7.html) |
| PT (3) | PT1645567E (cg-RX-API-DMAC7.html) |
| RO (1) | RO118885B1 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2265849C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1996039629A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022328B1 (en) | 1995-11-30 | 2006-04-04 | Australian Pork Limited | Therapeutic and diagnostic compositions |
| FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| BR0011292A (pt) * | 1999-05-13 | 2002-02-26 | Pfizer Prod Inc | Gene derivado de lawsonia e proteìnas, peptìdeos e polipeptìdeos sodc relacionados e seus usos |
| US7029683B1 (en) | 1999-05-13 | 2006-04-18 | Pfizer Products, Inc. | Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses |
| US7052697B1 (en) * | 1999-05-13 | 2006-05-30 | Agriculture Victoria Services Pty Ltd | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses |
| CA2372102A1 (en) * | 1999-05-13 | 2000-11-23 | Australian Pork Limited | Lawsonia derived gene and related omph polypeptides, peptides and proteins and their uses |
| BR0011294A (pt) * | 1999-05-13 | 2002-02-26 | Pfizer Prod Inc | Gene derivado lawsonia e polipeptìdeos, peptìdeos e proteìnas flge relacionados e seus usos |
| NZ515363A (en) * | 1999-05-13 | 2003-07-25 | Pfizer Prod Inc | Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses |
| US6605696B1 (en) * | 1999-10-22 | 2003-08-12 | Pfizer, Inc. | Lawsonia intracellularis proteins, and related methods and materials |
| AU9315101A (en) * | 2000-09-29 | 2002-04-08 | Univ Arizona | Improved vaccines for proliferative ileitis and methods of making and using the same |
| AUPR138100A0 (en) | 2000-11-10 | 2000-12-07 | Agriculture Victoria Services Pty Ltd | Novel therapeutic compositions for treating infection by lawsonia spp |
| NZ520600A (en) * | 2000-11-10 | 2004-08-27 | Agriculture Victoria Serv Pty | Novel therapeutic compositions for treating infection by Lawsonia spp |
| ATE501258T1 (de) * | 2000-12-20 | 2011-03-15 | Intervet Int Bv | Lawsonia intracellularis impfstoff |
| US20030087421A1 (en) * | 2001-07-11 | 2003-05-08 | Gebhart Connie J | Lawsonia intracellularis |
| JP2006501846A (ja) * | 2002-10-04 | 2006-01-19 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ローソニア・イントラセルラリス由来の核酸およびポリペプチド配列ならびに使用方法 |
| UA87665C2 (ru) * | 2003-07-25 | 2009-08-10 | Берингер Ингельхайм Ветмедика, Инк. | Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis |
| CA2536989A1 (en) | 2003-09-12 | 2005-03-24 | Akzo Nobel N.V. | Lawsonia intracellularis subunit vaccine |
| WO2005056586A1 (en) * | 2003-12-09 | 2005-06-23 | Intervet International B.V | Lawsonia intracellularis 26 kd subunit vaccine |
| JP2007537721A (ja) * | 2004-01-22 | 2007-12-27 | インターベツト・インターナシヨナル・ベー・ベー | ローソニア・イントラセルラーリスのサブユニットワクチン |
| EP1609870A1 (en) * | 2004-06-24 | 2005-12-28 | Boehringer Ingelheim Vetmedica Gmbh | Method of diagnosing lawsonia intracellularis |
| MY146476A (en) * | 2004-06-24 | 2012-08-15 | Boehringer Ingelheim Vetmed | Method of diagnosing lawsonia intracellularis |
| US20060021536A1 (en) * | 2004-07-30 | 2006-02-02 | Limin Song | Method for creating an absorbent article exhibiting a harmonic color scheme |
| KR100621882B1 (ko) * | 2004-09-30 | 2006-09-19 | 건국대학교 산학협력단 | 돼지 증식성 회장염 감염돈에서 로소니아인트라셀룰라리스 균을 분리하는 방법 |
| CA2586093A1 (en) * | 2004-11-24 | 2006-06-01 | Pharmacia & Upjohn Company Llc | Methods for cultivating lawsonia intracellularis |
| US20070212373A1 (en) * | 2004-12-08 | 2007-09-13 | Akzo Nobel N.V. | Lawsonia Intracellularis 26 Kd Subunit Vaccine |
| US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
| US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
| UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| US8398994B2 (en) | 2005-07-15 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia vaccine and methods of use thereof |
| MY180002A (en) | 2005-12-29 | 2020-11-19 | Boehringer Ingelheim Vetmedica Inc | Multivalent pcv2 immunogenic compositions and methods of producing compositions |
| CN101426522B (zh) | 2005-12-29 | 2014-11-12 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Pcv2免疫原性组合物用于减轻猪临床症状的用途 |
| US8470336B2 (en) * | 2006-05-25 | 2013-06-25 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of young animals against Lawsonia intracellularis infections |
| US20080241190A1 (en) * | 2006-11-13 | 2008-10-02 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of horses against lawsonia intracellularis |
| EP2859900A1 (en) | 2006-12-11 | 2015-04-15 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
| WO2008076915A2 (en) * | 2006-12-15 | 2008-06-26 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of pigs with pcv2 antigen |
| EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
| EP1958644A1 (en) * | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
| US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
| WO2009037262A2 (en) | 2007-09-17 | 2009-03-26 | Boehringer Ingelheim Vetmedica, Inc. | Method of preventing early lawsonia intracellularis infections |
| JP2011500034A (ja) * | 2007-10-12 | 2011-01-06 | ファイザー・インク | ロウソニア・イントラセルラリス（ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）を培養する方法 |
| CN101932336B (zh) * | 2007-12-31 | 2014-07-09 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 有外来氨基酸插入的pcv2 orf2病毒样颗粒 |
| EP2242511A4 (en) | 2008-01-23 | 2012-10-24 | Boehringer Ingelheim Vetmed | IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS |
| US20110033495A1 (en) * | 2008-02-15 | 2011-02-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
| TWI551295B (zh) | 2008-04-18 | 2016-10-01 | 英特威特國際股份有限公司 | 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗 |
| TWI449533B (zh) | 2008-04-18 | 2014-08-21 | Intervet Int Bv | 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗 |
| ES2534556T3 (es) * | 2008-07-22 | 2015-04-24 | Intervet International Bv | Bacteria Lawsonia intracellularis de un nuevo serotipo, vacuna basada en esa bacteria, anticuerpos adecuados para diagnosticar el nuevo serotipo de Lawsonia intracellularis e hibridomas para producir dichos anticuerpos |
| US8142760B2 (en) * | 2008-09-05 | 2012-03-27 | Nathan Len Winkelman | Vaccination for Lawsonia intracellularis |
| WO2011006880A1 (en) * | 2009-07-14 | 2011-01-20 | Intervet International B.V. | Lawsonia intracellularis propagation |
| AR078253A1 (es) * | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
| ES2606131T3 (es) | 2009-11-09 | 2017-03-22 | Intervet International B.V. | Método para cultivar bacterias Lawsonia intracellularis en células McCoy infectadas de forma persistente |
| EP2938747B1 (en) | 2012-12-28 | 2019-05-01 | Boehringer Ingelheim Vetmedica GmbH | Method of making a mycoplasma vaccine |
| CN105579060B (zh) | 2013-09-25 | 2021-03-16 | 硕腾服务有限责任公司 | Pcv2b趋异株疫苗组合物以及使用方法 |
| WO2015051099A1 (en) | 2013-10-02 | 2015-04-09 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 protein variant and virus like particles composed thereof |
| US10751405B2 (en) | 2015-02-04 | 2020-08-25 | Intervet Inc. | Vaccine for use against subclinical Lawsonia infection in a pig |
| ES2798282T3 (es) * | 2015-02-04 | 2020-12-10 | Intervet Int Bv | Una vacuna para usar contra la infección asintomática por Lawsonia en un cerdo |
| KR20180062468A (ko) * | 2016-11-18 | 2018-06-11 | 녹십자수의약품(주) | 신규한 로소니아 인트라셀룰라리스 균주 및 이의 용도 |
| EP3758740A1 (en) | 2018-02-28 | 2021-01-06 | Boehringer Ingelheim Vetmedica GmbH | Method for reducing skatole and/or indole in animals |
| KR20230044474A (ko) | 2020-07-24 | 2023-04-04 | 베링거 인겔하임 애니멀 헬스 유에스에이 인크. | 조합 돼지 백신 |
| EP4426342A1 (en) | 2021-11-01 | 2024-09-11 | Boehringer Ingelheim Vetmedica GmbH | Immunogenic gel compositions |
| WO2024068637A1 (en) | 2022-09-27 | 2024-04-04 | Intervet International B.V. | A method of culturing lawsonia intracellularis bacteria |
| WO2024260953A1 (en) * | 2023-06-23 | 2024-12-26 | Intervet International B.V. | A method of culturing lawsonia intracellularis bacteria |
| CN119185351B (zh) * | 2024-09-25 | 2025-09-16 | 武汉轻工大学 | Li0004蛋白靶点在制备抑制劳森菌感染细胞增殖的药物中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4132597A (en) * | 1976-06-09 | 1979-01-02 | Ab Medipharm | Method for cultivation of bacteria |
| US4237218A (en) * | 1979-02-09 | 1980-12-02 | Bio-Rad Laboratories, Inc. | Micro-carrier cell culture |
| JPS5991879A (ja) * | 1982-11-16 | 1984-05-26 | Hideaki Yamada | シユ−ドモナス属細菌の培養法 |
| DK594084A (da) * | 1984-12-12 | 1986-06-13 | Novo Industri As | Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning |
| JPH0644865B2 (ja) * | 1985-10-29 | 1994-06-15 | 三菱瓦斯化学株式会社 | カンピロバクタ−属細菌の培養方法 |
| US5338670A (en) * | 1986-07-28 | 1994-08-16 | The United States Of America As Represented By The Department Of Health And Human Services | Production of bordetella pertussis toxin with a low concentration of iron |
| IT1227657B (it) * | 1988-12-01 | 1991-04-23 | Mini Ricerca Scient Tecnolog | Antibiotici ab-021 e processo per la loro produzione |
| JPH0822221B2 (ja) * | 1988-12-28 | 1996-03-06 | 日東化学工業株式会社 | シュードモナス属細菌の培養法 |
| JPH02308754A (ja) * | 1989-05-24 | 1990-12-21 | Yakult Honsha Co Ltd | 乳発酵食品の製造法 |
| US5296221A (en) * | 1990-01-31 | 1994-03-22 | Sani-Ei Sucrochemical Co., Ltd. | Lactobacillus johnsonii ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations |
| WO1992007934A1 (en) * | 1990-11-01 | 1992-05-14 | Iowa State University Research Foundation, Inc. | Bacterial attenuation method and vaccine |
| SU1768637A1 (en) * | 1990-12-04 | 1992-10-15 | Inst Virusologii Im D I Ivanov | Strain of human immunodeficient virus 1-type for preparation of diagnostic preparation |
| CA2123222C (en) * | 1991-11-15 | 2001-02-27 | Donald A. Dearwester | Gram-negative bacterial vaccines |
| DE4208785A1 (de) * | 1992-03-19 | 1993-09-23 | Degussa | Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen |
| US5610059A (en) * | 1992-11-09 | 1997-03-11 | University Of Arizona | Etiological agent for porcine enteritis |
-
1996
- 1996-06-04 US US08/658,194 patent/US5885823A/en not_active Expired - Lifetime
- 1996-06-05 RU RU98100430/13A patent/RU2265849C2/ru active
- 1996-06-05 AU AU62627/96A patent/AU717045B2/en not_active Expired
- 1996-06-05 KR KR1020057003259A patent/KR100758614B1/ko not_active Expired - Lifetime
- 1996-06-05 EP EP20050023398 patent/EP1655607B1/en not_active Expired - Lifetime
- 1996-06-05 DE DE69634334T patent/DE69634334T2/de not_active Expired - Lifetime
- 1996-06-05 EP EP03022895.1A patent/EP1403643B2/en not_active Expired - Lifetime
- 1996-06-05 PL PL35816396A patent/PL187850B1/pl unknown
- 1996-06-05 AT AT96921391T patent/ATE289069T1/de active
- 1996-06-05 ES ES96921391T patent/ES2173055T3/es not_active Expired - Lifetime
- 1996-06-05 NZ NZ319994A patent/NZ319994A/xx not_active IP Right Cessation
- 1996-06-05 AT AT03022895T patent/ATE441863T1/de active
- 1996-06-05 PL PL35816296A patent/PL187849B1/pl unknown
- 1996-06-05 BR BRPI9612938A patent/BRPI9612938B8/pt not_active IP Right Cessation
- 1996-06-05 EP EP10150886.9A patent/EP2199795B1/en not_active Expired - Lifetime
- 1996-06-05 PL PL96358164A patent/PL189187B1/pl unknown
- 1996-06-05 DK DK03022895T patent/DK1403643T3/da active
- 1996-06-05 BR BRPI9608338-7A patent/BR9608338B1/pt active IP Right Grant
- 1996-06-05 EP EP96921391.7A patent/EP0843818B2/en not_active Expired - Lifetime
- 1996-06-05 RO RO97-02211A patent/RO118885B1/ro unknown
- 1996-06-05 DE DE0843818T patent/DE843818T1/de active Pending
- 1996-06-05 DK DK96921391T patent/DK0843818T3/da active
- 1996-06-05 PL PL96325872A patent/PL189250B1/pl unknown
- 1996-06-05 DK DK05023400.4T patent/DK1645567T4/en active
- 1996-06-05 PT PT05023400T patent/PT1645567E/pt unknown
- 1996-06-05 PL PL96358166A patent/PL189287B1/pl unknown
- 1996-06-05 JP JP50186797A patent/JP3765834B2/ja not_active Expired - Lifetime
- 1996-06-05 PL PL96358165A patent/PL189286B1/pl unknown
- 1996-06-05 CZ CZ19973899A patent/CZ295933B6/cs not_active IP Right Cessation
- 1996-06-05 KR KR1020057005243A patent/KR100544857B1/ko not_active Expired - Lifetime
- 1996-06-05 AT AT05023400T patent/ATE373015T1/de active
- 1996-06-05 DE DE122007000102C patent/DE122007000102I1/de active Pending
- 1996-06-05 PT PT96921391T patent/PT843818E/pt unknown
- 1996-06-05 DE DE69638016T patent/DE69638016D1/de not_active Expired - Lifetime
- 1996-06-05 EP EP05023400.4A patent/EP1645567B2/en not_active Expired - Lifetime
- 1996-06-05 KR KR1020067024337A patent/KR20060129549A/ko not_active Ceased
- 1996-06-05 DE DE69637251.7T patent/DE69637251T3/de not_active Expired - Lifetime
- 1996-06-05 WO PCT/US1996/009576 patent/WO1996039629A1/en not_active Ceased
- 1996-06-05 ES ES05023400.4T patent/ES2294620T5/es not_active Expired - Lifetime
- 1996-06-05 HU HU9900884A patent/HU230199B1/hu unknown
- 1996-06-05 CA CA2222643A patent/CA2222643C/en not_active Expired - Lifetime
- 1996-06-05 PT PT03022895T patent/PT1403643E/pt unknown
- 1996-06-05 KR KR1019970708990A patent/KR100513481B1/ko not_active Expired - Lifetime
- 1996-06-05 ES ES03022895T patent/ES2332587T3/es not_active Expired - Lifetime
-
1997
- 1997-12-18 BG BG102130A patent/BG64292B1/bg unknown
-
2005
- 2005-05-13 RU RU2005114739/13A patent/RU2305707C2/ru active
- 2005-10-19 JP JP2005304585A patent/JP3920300B2/ja not_active Expired - Lifetime
-
2006
- 2006-12-28 JP JP2006355093A patent/JP4263212B2/ja not_active Expired - Lifetime
-
2007
- 2007-12-21 FR FR07C0071C patent/FR07C0071I2/fr active Active
- 2007-12-21 LU LU91405C patent/LU91405I2/fr unknown
-
2008
- 2008-01-08 NL NL300331C patent/NL300331I2/nl unknown
- 2008-05-12 JP JP2008124788A patent/JP5078740B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG64292B1 (bg) | К"Л'ИВИРАН... НА LAWSONIA INTRACELLULARIS, ВАК'ИНИ 'Р...(tm)" LAWSONIA INTRACELLULARIS И ДИАГНО''И-НИ 'Р...Д''ВА | |
| CN1519311B (zh) | 胞内劳森氏菌培养、抗该菌的疫苗和诊断试剂 | |
| MXPA97009464A (en) | Culture of lawsonia intracellularis, vaccines against lawsonia intracellulares and agents of diagnost | |
| HK1081594B (en) | Lawsonia intracellularis cultivation in mccoy cell | |
| HK1067662B (en) | Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents | |
| HK1010911B (en) | Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents |